
Athenex ATNX
Country |
|
IPO year |
2017 |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
6.54 M |
Market Cap[1] |
$ 1.76 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Perrigo Company plc
PRGO
|
$ 16.63 | 0.91 % | $ 2.3 B | NYSE | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 7.18 | 0.67 % | $ 107 M | Nasdaq Global Select Market | ||
|
Evolus
EOLS
|
$ 7.1 | 4.85 % | $ 458 M | Nasdaq Global Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB | ||
|
Aurora Cannabis
ACB
|
$ 3.99 | 0.24 % | $ 219 M | NYSE | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Emergent BioSolutions
EBS
|
$ 6.38 | 3.98 % | $ 341 M | NYSE,SPB | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Pacira BioSciences
PCRX
|
$ 36.34 | 0.03 % | $ 1.62 B | Nasdaq Global Select Market,SPB | ||
|
Solid Biosciences
SLDB
|
$ 5.53 | 0.52 % | $ 484 M | Nasdaq Global Select Market,SPB | ||
|
Tilray
TLRY
|
$ 3.04 | 0.16 % | $ 340 M | Nasdaq Global Select Market | ||
|
TherapeuticsMD
TXMD
|
$ 1.9 | 0.06 % | $ 22 M | Nasdaq Global Select Market | ||
|
Veru
VERU
|
$ 2.3 | 0.41 % | $ 33.7 M | Nasdaq Capital Market | ||
|
Viatris
VTRS
|
$ 18.66 | 2.39 % | $ 21.4 B | Nasdaq Global Select Market,SPB | ||
|
cbdMD
YCBD
|
$ 0.36 | 1.71 % | $ 1.45 M | NYSE American | ||
|
Harrow Health
HROW
|
$ 27.28 | 5.54 % | $ 1 B | Nasdaq Global Market | ||
|
Canopy Growth Corporation
CGC
|
$ 0.71 | 0.65 % | $ 212 M | Nasdaq Global Select Market | ||
|
Rockwell Medical
RMTI
|
$ 7.43 | 4.18 % | $ 267 M | Nasdaq Global Market | ||
|
Organogenesis Holdings
ORGO
|
$ 1.0 | 0.78 % | $ 127 M | Nasdaq Capital Market | ||
|
SCYNEXIS
SCYX
|
$ 3.67 | 0.5 % | $ 183 M | Nasdaq Global Select Market | ||
|
Sundial Growers
SNDL
|
$ 1.25 | 3.31 % | $ 323 M | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 1.12 | 2.61 % | $ 1.89 M | Nasdaq Capital Market | ||
|
OrganiGram Holdings
OGI
|
$ 0.93 | 0.3 % | $ 88.6 M | Nasdaq Global Select Market | ||
|
Bausch Health Companies
BHC
|
$ 6.3 | 0.08 % | $ 2.34 B | NYSE | ||
|
Cronos Group
CRON
|
$ 3.21 | 0.31 % | $ 1.23 B | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.71 | 6.98 % | $ 3.05 M | NYSE American | ||
|
Relmada Therapeutics
RLMD
|
$ 3.1 | 0.15 % | $ 122 M | Nasdaq Global Select Market,SPB | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Assertio Holdings
ASRT
|
- | - | $ 150 M | Nasdaq Capital Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.